Lung Cancer

Seprase (FAP) is a critical therapeutic target in lung cancer owing to its overexpression on CAFs and tumor cells in the hypoxic tumor microenvironment. The approach by seprase (FAP) leads towards immune evasion, metastasis, and resistance towards chemotherapy/immunotherapy through ECM degradation and the secretion of immunosuppressive cytokines. Alfa Cytology provides end-to-end seprase (FAP)-targeted diagnostics and therapeutics for lung cancer.

Introduction to Lung Cancer

Seprase (FAP) target correlates mostly with lung cancer, where seprase (FAP) gene is highly expressed in lung cancers like non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Its expression occurs in the cancer-associated fibroblasts (CAFs) and promotes the tumor growth by extracellular matrix remodeling, angiogenesis, and immunosuppression. Due to its less expression rate in the normal tissues, seprase (FAP) remains an ideal target concerning lung cancer diagnosis and treatment. Final conclusions regarding promising antitumor activity of small-molecule inhibitors, radioligand therapy, and immunotherapy in preclinical and early clinical studies are still to be made.

Fig. 1 ⁶⁸Ga-FAPI-04 PET/CT and FAP immunostaining in non-small cell lung cancer. (Li, C., et al. 2024)

Seprase (FAP)-Targeted Drug Development for Lung Cancer

Disclaimer: Alfa Cytology focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

Alfa Cytology unites platforms such as 3D patient-derived organoid models using artificial intelligence-driven molecular design. These platforms provide seprase (FAP)-relevant comprehensive therapeutic services to lung cancer thereby fast-tracking your drug development.

Precision Therapy Development for Different Lung Cancer Types

One-Stop Solutions

Dianostic Development

Alfa Cytology is pioneers in undertaking FAP-targeted diagnostics focused on the discovery of new theranostic radiopharmaceuticals and the development of novel imaging agent.

Therapeutic Development

With a forward-thinking approach, we are developing several therapeutic strategies for FAP across small molecule, antibody, and RDCs and are advocating research into innovative therapies.

Alfa Cytology is a pioneer in the seprase (FAP) targeted solution aimed at lung cancer, from molecular discovery to preclinical studies. Partner with us to overcome barriers and unleash therapeutic potential. Please contact us for further inquiries on how we stand by with a full-service scope toward a successful drug discovery and development project.

For research use only.